Samantha Hamilton
Family · Stuart, FLNPI 1700277217
Payments from drug & device makers
Across 377 payments — averaging $19.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$1K
- AstraZeneca$763
- Bayer$759
- Amgen$469
- Lilly USA, LLC$452
- plus $3K from 34 others
What the payments were for
- Food & beverage$7,245100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 63 | $1,121 |
| Novo Nordisk | 69 | $1,084 |
| AstraZeneca | 31 | $763 |
| Bayer | 28 | $759 |
| Amgen | 24 | $469 |
| Lilly USA, LLC | 25 | $452 |
| Pfizer | 19 | $366 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $221 |
| GSK | 13 | $215 |
| Biohaven Pharmaceuticals, Inc. | 11 | $187 |
| Esperion Therapeutics, Inc. | 2 | $135 |
| Idorsia Pharmaceuticals US Inc | 7 | $123 |
| Optinose US, Inc. | 5 | $101 |
| Abbott | 5 | $100 |
| Jazz Pharmaceuticals Inc. | 7 | $100 |
| Astellas Pharma US Inc | 5 | $99 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $94 |
| Eisai Inc. | 5 | $86 |
| Shield Therapeutics Inc | 3 | $78 |
| Novartis | 3 | $59 |
| Currax Pharmaceuticals LLC | 3 | $44 |
| Corium, LLC | 2 | $43 |
| Collegium Pharmaceutical, Inc. | 2 | $37 |
| Dexcom, Inc. | 2 | $37 |
| Exact Sciences | 2 | $37 |
| Vivus LLC | 2 | $37 |
| Merck | 2 | $35 |
| Xeris Pharmaceuticals, Inc. | 2 | $34 |
| Biogen | 2 | $30 |
| Mylan Specialty L.p. | 2 | $29 |
| Johnson & Johnson | 1 | $27 |
| Adlon Therapeutics L.p. | 2 | $24 |
| Gilead | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Medtronic | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Almatica Pharma LLC | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,245 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 76 | $105,645 |
| EliquisApixaban | 42 | $49,002 |
| RybelsusSemaglutide | 13 | $32,446 |
| Repatha SureclickEvolocumab | 29 | $21,360 |
| XareltoRivaroxaban | 14 | $19,929 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $18,327 |
| MounjaroTirzepatide | 18 | $18,125 |
| KerendiaFinerenone | 17 | $17,078 |
| JardianceEmpagliflozin | 23 | $16,908 |
| TrulicityDulaglutide | 13 | $12,387 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $7,955 |
| Rosuvastatin Calcium | 323 | $4,417 |
| Levothyroxine Sodium | 235 | $2,568 |
| Atorvastatin Calcium | 323 | $2,406 |
| SynthroidLevothyroxine Sodium | 27 | $2,329 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,084 | $138,09189 claims |
| PfizerEliquis | $366 | $49,00242 claims |
| Lilly USA, LLCMounjaro, Trulicity | $452 | $30,51231 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $215 | $26,28229 claims |
| Johnson & JohnsonXarelto | $27 | $19,92914 claims |
| BayerKerendia | $759 | $17,07817 claims |
| AbbVieSynthroid | $1,121 | $2,32927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Stuart
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.